SpineThera will participate in the Medical Alley Association roundtable discussion of alternatives to opioids, which will be held on October 2nd, 2017 at 9 am in the Minnesota Senate Building.  The roundtable discussion will include Minnesota legislative leaders and will showcase pain management technologies developed by Minnesota companies.

Jeff Missling, CEO, will present an overview of SpineThera’s sustained-release injectable steroid, SX600, an investigational drug in development to treat low back pain.  SpineThera designed SX600 with the goal of providing patients long term back pain relief from a single epidural steroid injection.   60% of back pain patients have been reported to receive at least 1 opioid prescription within the first year of their diagnosis. 

About SpineThera:

SpineThera designs and develops sustained-release, injectable drugs to meet the unique safety requirements for administration in and near the spine. Our goal is to develop proprietary drugs that offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs. SX600, our lead product candidate, is an investigational drug.

About the event:

With the opioid crisis enveloping the nation, the Medical Alley Association is working with legislators to highlight alternatives that can be utilized to ensure that a patient can avoid exposure to addictive opioids.   A press conference with participating companies and legislative leaders will take place prior to the roundtable discussion.